DexTech Medical strengthens its organization, Andreas Segerros proposed as new Chairman of the Board

The Board of Directors of DexTech Medical AB (“DexTech” or “the Company”) has decided to strengthen the Company's organization with the main focus on future business based on DexTech's unique platform technology and research portfolio. Andreas Segerros is proposed as the new Chairman of the Board and will lead the work of further strengthening the Board with industry expertise and implementing a strengthening of the management. Andreas Segerros has long and solid experience with executive positions in the international pharmaceutical industry, in Europe, the USA and Japan.

   The changes are part of the development of DexTech and to realize the great values ​​contained in the Company's technology and drug candidates. Andreas Segerros is formally proposed at an Extraordinary General Meeting in May.

Preclinical and clinical research is proceeding according to the current plan.

"We see this as a very positive and natural step that will develop the Company to realize the great values ​​that have been created”, says CEO Anders R Holmberg.

For more information on DexTech, please contact:

Gösta Lundgren - CFO

DexTech Medical AB

Phone: +46 (0) 707104788

Email: gosta.lundgren@dextechmedical.com

This information is such information that DexTech Medical AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on April 6, 2022.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to outlicense the respective drug candidate no later than after the completion of a phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.